Immunic, Inc. (IMUX) operates as a clinical-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing novel oral immunology therapies designed to treat chronic inflammatory and autoimmune conditions. The company's core scientific pipeline focuses on small-molecule inhibitors—such as its lead candidate, vidofludimus calcium—which target specific intracellular pathways to modulate immune cell activation in diseases like relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and ulcerative colitis. By advancing these convenient oral treatments through rigorous global clinical trials, the company aims to offer patients alternatives to complex injectable biologic therapies.